Results 11 to 20 of about 11,226 (207)

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

Therapeutics and Clinical Risk Management, 2023
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN ...
Suzanne Lentzsch, Michael S Hughes
exaly   +3 more sources

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Frontiers in Oncology, 2021
Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by different
Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione   +6 more
doaj   +2 more sources

Daratumumab-induced transient myopic shift [PDF]

American Journal of Ophthalmology Case Reports, 2019
Purpose: To describe an unprecedented case of transient myopic shift induced by a chemotherapeutic agent, daratumumab. Observations: A 43-year-old emmetropic female with multiple myeloma experienced sudden onset of myopic shift during her first ...
Maria A. Mavrommatis, Hoon Jung, Ajai Chari, Bart Barlogie, James G. Chelnis   +4 more
doaj   +2 more sources

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro

Brain, Behavior, & Immunity - Health
Multiple myeloma is a haematological cancer characterised by the accumulation of clonal plasma cells in the bone marrow and is commonly treated with daratumumab, an anti-CD38 monoclonal antibody immunotherapy.
Harrison D. Collier-Bain, Annabelle Emery, Frankie F. Brown, Adam J. Causer, Rebecca Oliver, Rachel Eddy, Shoji Leach, John Graby, Daniel Augustine, Sally Moore, Josephine Crowe, James Murray, James E. Turner, John P. Campbell   +13 more
doaj   +3 more sources

Daratumumab [PDF]

Reactions Weekly, 2020
AbstractMultiple myeloma is a proliferative disorder of plasma cells in the bone marrow with excessive monoclonal protein production. Despite the evolution of multiple drugs and management strategies including maintenance and autologous stem cell transplantation, the long-term results still remain undesirable.
Vishnu Gopal, Biswajit Dubashi
  +10 more sources

Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience [PDF]

Cancer Reports
Background Daratumumab represents the first‐in‐class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM).
Oscar C. Y. Yang, Yi‐Hao Chiang, Caleb Gonshen Chen, Yu‐Cheng Chang, Ming‐Chih Chang, Huan‐Chau Lin, Johnson Lin, Ken‐Hong Lim   +7 more
doaj   +2 more sources

Daratumumab-based treatment for immunoglobulin light-chain amyloidosis [PDF]

, 2021
BACKGROUND Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells.
Sanchorawala V., Ahmadi T., Minnema M. C., Palladini G., Tran N., Wechalekar A. D., Rosenzweig M., Merlini G., Zhuang S. H., Lu J., Kim K., Suzuki K., Zonder J. A., Kim J. -S., Hansen T., Kwok F., Libby E., Qin X., Lee H. C., Shimazaki C., Crusoe E., Valent J., Manier S., Mollee P., Song K., Vasey S. Y., Cibeira M. T., Wong S. W., Bhutani D., Kastritis E., Goodman S. A., Vermeulen J., Huart A., Waxman A. J., Jamroziak K., Hungria V., Lam S., Weiss B. M., Tromp B., Bumma N., Beksac M., Dimopoulos M. A., Schonland S., Schecter J. M., Comenzo R. L., Jaccard A., Venner C. P., Gatt M. E., Roeloffzen W., Gibbs S.   +49 more
core   +9 more sources

Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Management of patients with refractory or frequently relapsing (r/r) immune thrombotic thrombocytopenic purpura (iTTP) remains challenging, with no established consensus on optimal therapeutic strategies.
Roman Schimmer, Jana van den Berg, Marissa Schraner, Alice Trinchero, Andreas Holbro, Johanna A. Kremer Hovinga, Jan-Dirk Studt   +6 more
doaj   +2 more sources

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma

Frontiers in Oncology, 2022
BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion
Francesca Bonello, Serena Rocchi, Serena Rocchi, Gregorio Barilà, Michela Sandrone, Marco Talarico, Marco Talarico, Elena Zamagni, Elena Zamagni, Matilde Scaldaferri, Susanna Vedovato, Cecilia Bertiond, Laura Pavan, Sara Bringhen, Francesco Cattel, Renato Zambello, Michele Cavo, Michele Cavo, Roberto Mina   +18 more
doaj   +1 more source

Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated Disorders. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Kaposi sarcoma herpes virus (KSHV) is associated with multiple clinical manifestations, including primary effusion lymphoma, an aggressive CD38+ B cell lymphoma with a plasmablastic phenotype. Case This case describes an antiretroviral therapy‐adherent person with HIV who presented with concurrent KSHV‐related disorders of Kaposi ...
Roberts K, Valiño Ramos P, Jindal S, Prasad V, Lee YS, Khanfar M, Griffith OL, Griffith M, Jiang J, Cesarman E, Rauch D, Simonson P, Odeny T, Ratner L.   +13 more
europepmc   +2 more sources